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Abstract  
Objective: The aim of this paper is to describe a conceptual framework for how to 
consider health equity in the GRADE (Grading Recommendations Assessment and 
Development Evidence) guideline development process.   
Study design and setting: Consensus-based guidance conducted with the GRADE 
working group and colleagues. 
Results: We developed consensus-based guidance to help address health equity when 
rating the certainty of synthesized evidence (i.e., quality of evidence). We propose five 
methods of assessing health equity explicitly: 1)  Include health equity as an outcome; 
2)  Consider patient-important outcomes relevant to health equity; 3)  Assess 
differences in the relative effect size of the treatment; 4)  Assess differences in baseline 
risk and hence the differing impacts on absolute effects; and  5) Assess indirectness of 
evidence to disadvantaged populations and/or settings.   
Conclusion: The most important priority for research is to identify and document 
examples where health equity has been considered explicitly in guidelines.  Although 
there is a weak evidence base for assessing health equity, this should not discourage 
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the explicit consideration of how guidelines and recommendations affect the most 
vulnerable members of society.    
 
Keywords: guidelines, health equity, systematic reviews, indirectness, GRADE 
guidelines,  
 
Running title: GRADE Equity: Rating certainty of synthesized evidence 
 
Key points 
● Considering health equity in rating the certainty in synthesized evidence requires 
a priori elaboration of the disadvantaged populations and settings of interest, and 
methods to assess both relative and absolute effects for these populations 
● GRADE judgments about directness require transparent reporting of how 
judgments were made 
1. Background 
Health inequities are differences in health that are not only unnecessary and avoidable 
but are also considered unfair and unjust [1] .  As described in the introductory paper in 
this series, we use the acronym PROGRESS Plus (Place of residence, 
Race/ethnicity/culture/language, Occupation, Gender/sex, Religion, Education, 
Socioeconomic status, or Social capital + personal, relational and time-dependent 
characteristics) to identify individual and context-specific characteristics across which 
health inequities may occur [2].   
Guideline panels need to decide early on whether they plan to develop equity-sensitive 
recommendations (as described in the introductory paper in this series).  Using explicit 
prompts may be helpful in this process [3]. In principle, considering health equity is 
important for two main types of guidelines: 1) universal interventions where health 
inequity is a concern [4-7]; and 2) targeted or dedicated interventions aimed at one or 
more disadvantaged populations that have experienced health inequities. An example 
of the latter is the Canadian immigrant health guidelines [8], developed to raise 
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awareness of migrant health needs and improve access to effective preventive 
screening.   
This paper provides guidance to address health equity when rating the certainty in 
synthesized evidence using the GRADE approach.  This paper is the third paper in a 
four-part series on health equity and GRADE, with the introduction [Welch et al], overall 
process [Akl et al] and evidence to decision methods [Pottie et al]. 
2. Existing guidance 
As discussed in the earlier two papers in this series, several authors have assessed 
how guidelines consider health inequity concerns[Welch et al this series, Akl et al this 
series. None of these papers focus on rating the certainty of synthesized evidence (i.e., 
quality of evidence) using the GRADE approach.   
3. GRADE certainty in synthesized evidence and health equity 
The GRADE approach of presenting the evidence by outcome and the associated 
certainty (i.e., quality of evidence) involves the production of summary tables. These 
tables include evidence profiles (with details on the rating of certainty for each outcome) 
and summary of findings (SoF) tables that are intended for the public, patients, 
purchasers, payers, practitioners, product-makers (e.g. manufacturers, industry) and 
policy-makers [9].   
Five methods can be used to assess health equity with the GRADE approach:  
a) Include health equity as an outcome 
b) Consider patient-important outcomes relevant to health equity 
c) Assess differences in the magnitude of effect in relative terms between 
disadvantaged and more advantaged individuals or populations 
d) Assess differences in baseline risk and hence the differing impacts on 
absolute effects for disadvantaged individuals or populations 
e) Assess indirectness of evidence to disadvantaged populations and/or 
settings; 
3a) Consider including health equity as an outcome for the SoF tables 
If health inequity is considered an important concern by relevant stakeholders, then 
health equity could be included as an outcome in the PICO (Population, Intervention, 
Comparison, Outcome) questions, analytic framework and SoF table. In doing so, 
guideline developers must recognize that health equity is primarily assessed with a 
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subgroup analysis. The developers should also note that this may risk excluding other 
patient important outcomes, if SoF tables are limited to only seven outcomes as 
recommended by GRADE.  For example, the NICE guideline on maternal and child 
nutrition identified impact on health inequalities as one of its key priorities, and framed 
its key question as: “What nutritional interventions are effective in improving the health 
of pre-conceptual, pregnant and postpartum mothers and children (up to 5 years) and 
reducing nutrition-related health inequalities” [10].  By including health equity as an 
outcome in the SoF table, it is easier for guideline panels to find the information (or lack 
thereof) about health equity, and consider it in their deliberations. 
The direction and size of the effect on health equity is influenced by decisions such as 
the reference comparator group, use of relative or absolute measures, and whether the 
outcome is a desirable or undesirable event [11, 12].  For example, the choice of 
absolute or relative effects can change the conclusions about health inequalities.  This 
is illustrated by gender disparity in stomach cancer mortality rates in the United States 
between 1930 and 2000 has decreased when looking at absolute differences (the rates 
for both men and women have declined). However, the relative risk for men compared 
to women has increased (increased disparity, male/female ratio)[13]. 
A lack of evidence about a critical health equity outcome should not be a reason to omit 
this from the SOF table.  Indeed, this should be explicitly identified as an empty row, 
highlighting the need for further research to answer questions about health equity.   
Example 1: The Community Guide Water fluoridation guideline  [14] included 
“health disparities” as an outcome in the analytic framework and the SoF table 
because the Community Task Force placed a high value on reducing 
socioeconomic disparities in dental caries.  Socioeconomic disparities were 
measured as the difference in absolute terms of a continuous outcome (caries).  
The evidence review found three studies that provided insufficient evidence 
about socioeconomic disparities to draw conclusions, highlighting a gap in the 
evidence-base (Table 1). 
Example 2: “Equity impact” was the primary outcome of a systematic review on 
interventions to reduce smoking in adults [15].  Equity impact was assessed as 
the difference in the magnitude of a dichotomous outcome in absolute terms, 
defined as a difference in absolute effect on prevalence in lower socioeconomic 
status compared to higher socioeconomic status. This review showed that while 
increases in price or taxes reduced health inequities in smoking, mass media 
campaigns were more likely to worsen health inequities.  This type of review 
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provides evidence that could be used to include impact on health equity as an 
outcome of interventions. 
3b) Consider patient-important outcomes relevant to health equity 
As described in the previous paper in our series[Akl et al in this series], the evidence 
synthesis process should consider the relative importance of different outcomes, 
determined with input from stakeholders representing disadvantaged groups.  The 
evidence-base for these outcomes should then be assessed.  Examples of patient 
importance and health equity were provided in the previous paper in this series such as 
the importance of inconvenience of a subcutaneous chelation pump for people with 
sickle cell disease [described in Akl et al in this series]. 
3c) Assess differences in the magnitude of effect in relative terms between 
disadvantaged and more advantaged individuals or populations 
Average effects obscure differences between subpopulations- that is, subgroup effects 
may exist.  Examining whether effects differ across socioeconomic status or other 
variables relating to health inequity requires investigating heterogeneity in the treatment 
effect- for example, using statistical approaches such as meta-regression or subgroup 
analysis.  However, such results may not be available in the literature. There is 
evidence that systematic reviews under-report subgroup analyses from primary studies 
[16, 17]. Furthermore, many primary studies fail to assess possible subgroup effects 
related to disadvantaged populations. 
Relative effects are usually similar across diverse populations and settings, and 
spurious subgroup effects are common [18].  Thus, if analysis suggests an apparent 
subgroup effect, it is important to assess the credibility of the apparent effect [19].   Sun 
and colleagues describe several criteria to help do this such as determining a priori 
which subgroup analysis to conduct, finding a low p-value associated with a statistical  
test for interaction, and providing results from within study comparisons [20, 21]. Sun et 
al also showed that subgroup analyses reported in the literature rarely meet these 
criteria. Evidence synthesis that involves subgroup analyses should therefore consider 
the full set of credibility issues, using an appropriate checklist, and avoid making 
conclusions based on chance findings (Table 2).  
If applying the criteria in Table 2 leads to a conclusion that the subgroup effect is 
credible, the guideline panel should provide different estimates of relative and absolute 
effect for the subgroups.  The panel should then consider making different 
recommendations for patients in these subgroups, or consider whether 
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recommendations that apply to the overall population need to be adapted to enhance 
equity. When the credibility of subgroup effects is low, the guideline panel may suggest 
that further research is needed. Few subgroup analyses meet all of these criteria; 
however, when most criteria are met, decision-making must consider the likely 
existence of subgroup effects.   
Example: Hypertension and ethnicity 
The Eighth Joint National Committee (JNC 8) guideline on management of 
hypertension recommends a calcium channel blocker or thiazide-type diuretic as 
initial therapy in the black hypertensive population (whereas an angiotensin-
converting enzyme inhibitor, angiotensin receptor blocker, calcium channel 
blocker, or thiazide-type diuretic is recommended for others with hypertension) 
[22].  This recommendation was based on a pre-specified subgroup analysis of 
the ALLHAT trial (n=18,102 participants, 35% black [23]) that showed stroke was 
51% (95% CI 1.22-1.86) greater for blacks treated with an ACE inhibitor first 
compared to those treated with a calcium channel blocker.  The guideline panel 
rated this subgroup effect as moderate quality evidence.  Had the panel not 
identified this subgroup effect, use of an ACE inhibitor as a first line agent would 
have increased health disparities between black and white ethnic groups. 
3d) Assess differences in baseline risk and hence the differing impacts on 
absolute effects for disadvantaged individuals or populations 
A higher baseline risk of adverse events in any population may lead to greater absolute 
harm from an intervention and conversely a higher baseline prevalence of the outcome 
of interest may lead to greater absolute benefit  [24]. The SoF table should present the 
baseline risks and risk differences for each relevant population, and provide supporting 
evidence. Since disadvantaged populations have a disproportionate burden of almost all 
health conditions, it is particularly important to consider the baseline risk for these 
populations.  Baseline risk of adverse event rates or for the outcomes of interest for 
specific populations are best assessed using the most robust observational data on the 
actual population rather than from randomized trials.  GRADE guidance regarding 
assessing certainty of estimates of risk from broad populations is available [25, 26]. 
Example 1: WHO guidelines on vitamin A supplementation in children 6-59 
months 
In 2011 WHO recommended vitamin A supplementation for children aged 6 
months to 5 years in countries where vitamin A deficiency is a public health 
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problem (strong recommendation) [27].  This was based on findings of a 
Cochrane review with a relative risk for all-cause mortality of 0.76 (95% CI: 0.69 
to 0.83).  The baseline risk of all-cause mortality was estimated at 0/1000 in low 
risk populations and 90/1000 in high risk populations (with vitamin A deficiency), 
based on control group event rates in the trials.  Thus the absolute effects in 
terms of numbers of deaths prevented with vitamin A compared to the control 
group were 0/1000 for low risk and 22/1000 for high risk populations.   
Example 2: National guide to a preventive health assessment for Aboriginal 
and Torres Strait Islander people  
In Australia, a guideline panel sought to determine the optimal age at which to 
begin a series of preventive interventions in the Australian Aboriginal and Torres 
Strait Islander population.  The panel recommended preventive interventions at 
an earlier age than the general population on the basis of higher prevalence of 
preventable diseases in Aboriginal and Torres Strait Islander populations.  For 
example, type II diabetes is 3-4 times more common than in the general 
Australian population at all ages, leading to a recommendation for screening 
starting from age 18, instead of age 40 for the general population [28]. 
3e) Assess indirectness of evidence to disadvantaged populations 
GRADE quality (or certainty) “reflects our confidence that the estimates of the effect are 
correct. In the context of recommendations, quality reflects our confidence that the 
effect estimates are adequate to support a particular recommendation. “Quality” as used 
in GRADE means more than risk of bias and so may also be compromised by 
imprecision, inconsistency, indirectness of study results, and publication bias.” [29].  
Qualitative evidence may also be important when considering health equity.  Certainty 
for qualitative evidence synthesis can be rated using the CerQUAL tool [30] in which the 
domain “relevance” is most closely aligned with directness.  
Indirectness refers to the comparability between the population, the intervention, or the 
outcomes measured in research studies and those under consideration in a guideline or 
systematic review [31]. The GRADE approach evaluates the lack of directness as 
“Indirectness”.  Direct evidence may be lacking because some populations may not 
represent a large proportion of trial populations (e.g. migrants and refugees) and data 
are unlikely to be disaggregated for specific subgroups.  Direct evidence may also be 
lacking because some populations are explicitly excluded from trials, such as pregnant 
women and people with multiple morbidities [32-35]. Since multiple morbidities are more 
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common in socioeconomically disadvantaged people [36], this may result in 
disproportionate exclusion of disadvantaged populations from trials.   When direct 
evidence for the relevant disadvantaged population is not available, guideline 
developers will have to evaluate the indirectness of evidence obtained from other 
populations [37].   
As a rule, certainty of the evidence should not be rated down for indirectness for 
population differences unless there are compelling reasons to anticipate differences in 
effect due to biology/physiology, sociocultural influences or setting-specific resource 
issues that impact the effectiveness or harms of the intervention. In other words, one 
anticipates a different subgroup effect in either relative or absolute impact of treatment, 
though evidence is not available to make a formal assessment. (If it were, it should be 
formally assessed, as in 3c and 3d).  Guideline panels need to consider that rating 
down for indirectness could in itself increase inequities if this leads to less use of an 
effective intervention by disadvantaged groups.  In other words, lower certainty in effect 
estimates may lead to a weak recommendation and therefore under-use of a beneficial 
treatment.  Rating down for indirectness should therefore be done cautiously since 
effective interventions are needed even more in some populations that are often 
excluded from trials, such as those with multiple morbidities. 
Example 1: Canadian migrant guidelines not rated down for indirectness 
The quality of the evidence was not rated down for indirectness in the Canadian 
migrant guideline addressing screening for latent TB; the panel considered the 
evidence not to be indirect for migrants. Although no migrants were included in 
studies of intervention effectiveness, the developers did not expect different 
relative effects [38]. 
Example 2: CDC Guidelines for brief alcohol counselling for people with 
HCV infection rated down for indirectness  
The Centers for Disease Control and Prevention recommended brief alcohol 
screening and counselling for all person with HCV infection, based on a 
systematic review of 22 randomized trials which found a reduction of alcohol 
consumption of 38.42% (95% CI = 30.91–65.44) more than the control groups 
after 1 year.  This evidence was rated down for indirectness by the guideline 
panel because none of the trials included persons with HCV infection [39]. 
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4. Methodologic challenges  
In developing this guidance, we identified a number of methodologic challenges. Firstly, 
assessing effects on health equity is not a linear process.  There may be a need to 
revisit the focus of the guideline during the evidence review process, including the 
consideration of important disadvantaged groups.  NICE does this explicitly by revisiting 
their key questions regarding health equity throughout the process. 
Secondly, there are often limitations in the underlying evidence-base including poor 
reporting of sociodemographic characteristics [40, 41], under-reporting of subgroup 
analyses that are not statistically significant [21, 41], and use of multivariable models 
that may be over-adjusted for effect mediators, and / or include unnecessary collinear 
variables [42].  Lack of evidence on whether the effects are consistent or different for 
disadvantaged populations makes it difficult to judge indirectness and rate certainty of 
evidence. When the evidence-base is insufficient to assess effects on health equity, 
guideline panels need to make these limitations explicit and transparently report how 
they made judgments. 
Thirdly, epidemiologic evidence addressing baseline risk for specific disadvantaged 
groups may be difficult to obtain for the population or geographic region for which the 
recommendations are being developed.   Health systems at local, regional and national 
levels do not have consistent or reliable methods for reporting health status across all 
sociodemographic indicators of interest.   Guideline panels should transparently report 
how they determined baseline risk estimates. 
Fourthly, assessing directness of evidence depends on the clinical and methodological 
expertise and judgment of SoF developers.  The GRADE Guideline Development Tool 
(GDT) includes an explicit checklist when producing SoFs to ask whether the evidence 
is direct across population, intervention, comparison and outcome, and document the 
decision for rating down, if performed.   
5. Research agenda 
The most important research priority is to systematically identify further examples of 
how guideline panels have assessed health equity considerations and incorporated 
these assessments into recommendations using transparent methods.  For example, all 
WHO guidelines make their evidence to recommendation tables and SoFs publicly 
available for research such as this.  These assessments could provide examples of 
whether, and how, the five issues (a-e) above have been considered for different 
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situations, such as assessing the credibility of subgroup analyses and judging 
indirectness for disadvantaged populations. 
In conclusion, the GRADE process provides a structured approach to assess effects on 
health equity.  Health equity considerations warrant increased use of these methods in 
systematic reviews and guidelines.  The findings of assessing health equity using these 
five steps in guideline development provides a basis for judging “impact on equity” 
which is part of the DECIDE framework, and details about this process are covered in 
the fourth paper of this series [Pottie et al].    
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Table 1. Effect of Community Water Fluoridation on socioeconomic health 
inequities in caries [14] 
Outcome Measure Evidence  
Health equity as 
measured by 
socioeconomic 
disparities in caries 
% caries reduction 
Inconsistent results on 
socioeconomic disparities (3 
studies) 
dmft/DMFT 
No data on socioeconomic 
disparities 
DMFT/dmft – Decayed, Missing or Filled Teeth 
Upper case refers to permanent teeth; lower case to primary teeth 
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Table 2: Checklist for assessing credibility of subgroup analyses [43] 
 
Design 
Is the subgroup variable a characteristic measured at baseline or after 
randomization? 
Is the effect suggested by comparisons within rather than between studies? 
Was the hypothesis specified a priori? 
Was the direction of the subgroup effect specified a priori 
Was the subgroup effect one of a small number of hypothesized effects tested? 
Analysis 
Does the interaction test suggest a low likelihood that chance explains the 
apparent subgroup effect? 
Is the significant subgroup effect independent? 
Context 
Is the size of the subgroup effect large? 
Is the interaction consistent across studies? 
Is the interaction consistent across closely related outcomes within the study? 
Is there indirect evidence that supports the hypothesized interaction (biological 
rationale)? 
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